Outcome from prospective trials designed for older ALL patients
| Reference . | Year . | Age (y) . | Ph+ . | Patients (N) . | CR rate (%) . | Early death . | Failure . | CCR* . | DFS* . | OS† . |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 | 1996 | 60-73 (64) | Yes | 22 | 59 | 18% | 14% | 12 | 9 | 20% (2 y) |
| 23 | 1997 | 55-86 (67) | Yes | 40 | 85 | n.r. | n.r. | n.r. | 14 | 16% (2 y) |
| 24 | 2002 | 65 (55-81) | Yes | 58 | 43 | 10% | 47% | 5 | 10 | n.r. |
| 17 | 2004 | 69 (61-79) | Yes | 17 | 76 | 17% | 6% | 20 | 21 | 38% (2 y) |
| 19 | 2007 | 65 (56-77) | No | 33 | 58 | 36% | 6% | 46% (2 y) | 7 | 39% (1 y) |
| 20 | 2008 | 66 (60-78) | Yes | 17 | 71 | 29% | 0% | 82% (1 y) | n.r. | 71% (1 y) |
| 25 | 2008 | 66 (56-73) | No | 54 | 85 | 0% | 15% | 9 | n.r. | 61% (1 y) |
| 18 | 2011 | No | n.r. | |||||||
| Arm 1 | 68 (55-77) | 31 | 90 | 7% | 3% | 32% (2 y) | 35% (2 y) | |||
| Arm 2 | 66 (60-80) | 29 | 72 | 10% | 17% | 52% (2 y) | 24% (2 y) | |||
| 14 | 2012 | 57 (55-85) | No | 268 | 76 | 14% | 10% | 32% (5 y) | n.r. | 23% (5 y) |
| 21 | 2016 | 58 (51-72) | Yes | 30 | 67 | 3% | 30% | n.r. | 52% (2 y) | 52% (2 y) |
| 22 | 2016 | 66 (56-79) | No | 54 | 74 | 14% | 14% | n.r. | 8; 24% (2 y)‡ | 12; 30% (2 y)‡ |
| Reference . | Year . | Age (y) . | Ph+ . | Patients (N) . | CR rate (%) . | Early death . | Failure . | CCR* . | DFS* . | OS† . |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 | 1996 | 60-73 (64) | Yes | 22 | 59 | 18% | 14% | 12 | 9 | 20% (2 y) |
| 23 | 1997 | 55-86 (67) | Yes | 40 | 85 | n.r. | n.r. | n.r. | 14 | 16% (2 y) |
| 24 | 2002 | 65 (55-81) | Yes | 58 | 43 | 10% | 47% | 5 | 10 | n.r. |
| 17 | 2004 | 69 (61-79) | Yes | 17 | 76 | 17% | 6% | 20 | 21 | 38% (2 y) |
| 19 | 2007 | 65 (56-77) | No | 33 | 58 | 36% | 6% | 46% (2 y) | 7 | 39% (1 y) |
| 20 | 2008 | 66 (60-78) | Yes | 17 | 71 | 29% | 0% | 82% (1 y) | n.r. | 71% (1 y) |
| 25 | 2008 | 66 (56-73) | No | 54 | 85 | 0% | 15% | 9 | n.r. | 61% (1 y) |
| 18 | 2011 | No | n.r. | |||||||
| Arm 1 | 68 (55-77) | 31 | 90 | 7% | 3% | 32% (2 y) | 35% (2 y) | |||
| Arm 2 | 66 (60-80) | 29 | 72 | 10% | 17% | 52% (2 y) | 24% (2 y) | |||
| 14 | 2012 | 57 (55-85) | No | 268 | 76 | 14% | 10% | 32% (5 y) | n.r. | 23% (5 y) |
| 21 | 2016 | 58 (51-72) | Yes | 30 | 67 | 3% | 30% | n.r. | 52% (2 y) | 52% (2 y) |
| 22 | 2016 | 66 (56-79) | No | 54 | 74 | 14% | 14% | n.r. | 8; 24% (2 y)‡ | 12; 30% (2 y)‡ |
Arm 1, continuous infusion doxorubicin; Arm 2, pegylated doxorubicin; CCR, continuous complete remission; DFS, disease-free survival; n.r., not reported; OS, overall survival; Ph+, Ph/BCR–ABL1-positive ALL included yes or no.
Median months or probability.
Probability.
Estimated from Kaplan-Meier curve.